newsfilter
← Latest News
GlobeNewswire·

Olema Oncology Reports Third Quarter 2025 Financial and Operating Results

Announced new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib in ER+/HER2- metastatic breast cancerInitiated OPERA-02 Phase 3 trial of palazestrant in combination with